SCHEMBL14825527

SCHEMBL14825527

CCOC(=O)c1cccc(CN2CCN(C(c3ccccc3)c3ccccc3F)CC2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
OPRD1 P41143 4/20 0.46
KCNH2 Q12809 2/20 0.44
CYP1A2 P05177 1/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 1/20 0.41
POLB P06746 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRK1 P41145 1/20 0.41
OPRL1 P41146 1/20 0.41
CACNA2D1 P54289 2/20 0.39
CACNA1B Q00975 2/20 0.39
CACNB1 Q02641 2/20 0.39
CACNA1C Q13936 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825497 0.94 CYP1A2 (0.45) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825614 0.89 ATM (0.53) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825531 0.87 ATM (0.53) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825540 0.87 OPRD1 (0.48) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825668 0.87 OPRD1 (0.48) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825513 0.87 OPRD1 (0.48) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825846 0.87 OPRD1 (0.51) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825481 0.84 CYP1A2 (0.44) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825469 0.83 CACNA2D1 (0.53) ATMMEN1KMT2AOPRD1KCNH2
SCHEMBL14825496 0.82 ATM (0.47) ATMMEN1KMT2AOPRD1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 US disclosed
EP-2578569-B1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARM CO LTD (JP) 2015-10-28 EP disclosed
EP-2578569-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA Pharmaceutical Co., Ltd. (JP) 2013-04-10 EP disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 ATM 3898/4885MEN1 2318/4885KMT2A 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.